Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Corneal lifting (CL): new technique to treat keratoconus - long-term results

Search Title by author or title

Session Details

Session Title: Cornea: Surgical II

Session Date/Time: Sunday 08/10/2017 | 14:30-16:00

Paper Time: 14:42

Venue: Room 3.6

First Author: : M.Cosentino ARGENTINA

Co Author(s): :                        

Abstract Details

Purpose:

To introduce a new technique and technology to treat corneal ectasia and to analyze long- term refractive results.

Setting:

Clinica Carriazo, Barranquilla, Colombia and Instituto de la Vision, Buenos Aires, Argentina

Methods:

Anesthetic drops are instilled and 8 mm diameter open crescentic mask is placed. This mask is aligned with the patient's pupil. A platform developed for this purpose is used to perform the ablation (180, 270 and 360 degrees) through the mask. Once ablation is completed the edges of the resection are sutured with interrupted stitches.

Results:

A prospective analysis of 63 keratoconus cases was performed. Age was 30.83±12.65 years-old. Corneal thinnest point was 442.35± 85.13 µm. Preoperative uncorrected visual acuity (UCVA) was 0.04 ± 0.06 and best spectacle corrected visual acuity (BSCVA) was 0.33 ± 0.15; HOA was 5.22 ± 1.87µm and Coma was 5.97 ± 4.43µm. At 2 years, UCVA was 0.21 ± 0.18 (P<0.00001); BSCVA was 0.72 ± 0.45 (P<0.000001); HOA and Coma were 0.62 ± 0.41 µm and 3.39 ± 1.93 µm respectively. Decrease of anterior chamber depth was -0.38 ± 0.15 mm. Also, we analyzed predictability, safety and efficacy parameters.

Conclusions:

Progression of keratoconus means increasing of anterior chamber depth due to the posterior corneal steepening, corneal thinning and irregular astigmatism. CL is a safe technique. It produces corneal flattening, decrease of anterior chamber depth and reduction of optical aberrations. Regarding CL wide optical zone, it offers a possibility to perform refractive complementary procedures and it allows surgeons to create a “normal corneal profile”.

Financial Disclosure:

receives nonNONEmonetary benefits from a company producing, developing or supplying the product or procedure presented.

Back to previous